354 related articles for article (PubMed ID: 30146162)
1. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.
Minzel W; Venkatachalam A; Fink A; Hung E; Brachya G; Burstain I; Shaham M; Rivlin A; Omer I; Zinger A; Elias S; Winter E; Erdman PE; Sullivan RW; Fung L; Mercurio F; Li D; Vacca J; Kaushansky N; Shlush L; Oren M; Levine R; Pikarsky E; Snir-Alkalay I; Ben-Neriah Y
Cell; 2018 Sep; 175(1):171-185.e25. PubMed ID: 30146162
[TBL] [Abstract][Full Text] [Related]
2. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia.
Wang K; Jiang M; Liu H; Meng C; Li M; Lu H
Bioorg Chem; 2024 Jun; 147():107319. PubMed ID: 38593529
[TBL] [Abstract][Full Text] [Related]
4. Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax.
Gaur T; Poddutoori R; Khare L; Bagal B; Rashmi S; Patkar N; Tembhare P; Pg S; Shetty D; Dutt A; Zhang Q; Konopleva M; Platzbeckar U; Gupta S; Samajdar S; Ramchandra M; Khattry N; Hasan SK
J Exp Clin Cancer Res; 2023 Jul; 42(1):186. PubMed ID: 37507802
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia.
Ebert BL; Krönke J
N Engl J Med; 2018 Nov; 379(19):1873-1874. PubMed ID: 30403945
[No Abstract] [Full Text] [Related]
6. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
7. Mediator kinase inhibition further activates super-enhancer-associated genes in AML.
Pelish HE; Liau BB; Nitulescu II; Tangpeerachaikul A; Poss ZC; Da Silva DH; Caruso BT; Arefolov A; Fadeyi O; Christie AL; Du K; Banka D; Schneider EV; Jestel A; Zou G; Si C; Ebmeier CC; Bronson RT; Krivtsov AV; Myers AG; Kohl NE; Kung AL; Armstrong SA; Lemieux ME; Taatjes DJ; Shair MD
Nature; 2015 Oct; 526(7572):273-276. PubMed ID: 26416749
[TBL] [Abstract][Full Text] [Related]
8. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.
Rahaman MH; Yu Y; Zhong L; Adams J; Lam F; Li P; Noll B; Milne R; Peng J; Wang S
Invest New Drugs; 2019 Aug; 37(4):625-635. PubMed ID: 30194564
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7.
Hu S; Marineau JJ; Rajagopal N; Hamman KB; Choi YJ; Schmidt DR; Ke N; Johannessen L; Bradley MJ; Orlando DA; Alnemy SR; Ren Y; Ciblat S; Winter DK; Kabro A; Sprott KT; Hodgson JG; Fritz CC; Carulli JP; di Tomaso E; Olson ER
Cancer Res; 2019 Jul; 79(13):3479-3491. PubMed ID: 31064851
[TBL] [Abstract][Full Text] [Related]
10. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
Thomas D; Powell JA; Vergez F; Segal DH; Nguyen NY; Baker A; Teh TC; Barry EF; Sarry JE; Lee EM; Nero TL; Jabbour AM; Pomilio G; Green BD; Manenti S; Glaser SP; Parker MW; Lopez AF; Ekert PG; Lock RB; Huang DC; Nilsson SK; Récher C; Wei AH; Guthridge MA
Blood; 2013 Aug; 122(5):738-48. PubMed ID: 23775716
[TBL] [Abstract][Full Text] [Related]
11. Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor.
Zhang J; Liu W; Zou C; Zhao Z; Lai Y; Shi Z; Xie X; Huang G; Wang Y; Zhang X; Fan Z; Su Q; Yin J; Shen J
Clin Cancer Res; 2020 Jun; 26(11):2681-2692. PubMed ID: 31937612
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models.
Wang L; Hu C; Wang A; Chen C; Wu J; Jiang Z; Zou F; Yu K; Wu H; Liu J; Wang W; Wang Z; Wang B; Qi Z; Liu Q; Wang W; Li L; Ge J; Liu J; Liu Q
Invest New Drugs; 2020 Oct; 38(5):1272-1281. PubMed ID: 31872348
[TBL] [Abstract][Full Text] [Related]
13. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
[TBL] [Abstract][Full Text] [Related]
14. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
Gao Y; Gao J; Li M; Zheng Y; Wang Y; Zhang H; Wang W; Chu Y; Wang X; Xu M; Cheng T; Ju Z; Yuan W
J Hematol Oncol; 2016 Apr; 9():36. PubMed ID: 27071307
[TBL] [Abstract][Full Text] [Related]
15. CKIα ablation highlights a critical role for p53 in invasiveness control.
Elyada E; Pribluda A; Goldstein RE; Morgenstern Y; Brachya G; Cojocaru G; Snir-Alkalay I; Burstain I; Haffner-Krausz R; Jung S; Wiener Z; Alitalo K; Oren M; Pikarsky E; Ben-Neriah Y
Nature; 2011 Feb; 470(7334):409-13. PubMed ID: 21331045
[TBL] [Abstract][Full Text] [Related]
16. Casein kinase 1α inhibits p53 downstream of MDM2‑mediated autophagy and apoptosis in acute myeloid leukemia.
Xu W; Huang Z; Gan Y; Chen R; Huang Y; Xue B; Jiang S; Yu Z; Yu K; Zhang S
Oncol Rep; 2020 Nov; 44(5):1895-1904. PubMed ID: 32901886
[TBL] [Abstract][Full Text] [Related]
17. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
Lee DJ; Zeidner JF
Expert Opin Investig Drugs; 2019 Nov; 28(11):989-1001. PubMed ID: 31612739
[No Abstract] [Full Text] [Related]
19. Activating p53 and Inhibiting Superenhancers to Cure Leukemia.
Ball B; Abdel-Wahab O
Trends Pharmacol Sci; 2018 Dec; 39(12):1002-1004. PubMed ID: 30454768
[TBL] [Abstract][Full Text] [Related]
20. CDK9 inhibitors in acute myeloid leukemia.
Boffo S; Damato A; Alfano L; Giordano A
J Exp Clin Cancer Res; 2018 Feb; 37(1):36. PubMed ID: 29471852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
